A novel approach to corneal repair, utilizing genetically modified bacteria delivered via eye drops, is showing promise in early research. Scientists at the University of Pittsburgh are pioneering this “living eye drop” concept, aiming to provide a sustained, localized treatment for corneal damage and potentially revolutionize how ocular injuries are addressed. The research, led by Anthony St. Leger, PhD, represents a significant step toward what researchers are calling “living medicine” for the eye.
The cornea, the clear front surface of the eye, is vulnerable to injury from scratches, infections and other trauma. Current treatments often involve topical medications or, in severe cases, corneal transplants. This fresh approach seeks to harness the power of the eye’s natural microbiome – the community of microorganisms that live on its surface – to promote healing. The team’s perform focuses on Corynebacterium mastitidis, a bacterium naturally found in the eye, and modifying it to release an anti-inflammatory substance directly at the site of injury. This localized delivery could minimize side effects and maximize therapeutic benefit.
Engineering Bacteria for Corneal Health
Dr. St. Leger, an Associate Professor in the Department of Ophthalmology at the University of Pittsburgh School of Medicine, explained that This represents the first demonstration of a genetically modified microbe living on the ocular surface being used to deliver a therapeutic agent to improve eye health. According to research published in bioRxiv [Preprint] on March 18, 2025, the modified bacteria release a substance that helps to reduce inflammation and promote tissue regeneration. The goal is to create a treatment that can be applied once and then continuously protect and aid in the healing process. The research builds on the understanding that the ocular microbiome plays a crucial role in maintaining local immunity and preventing infection, a historically understudied area of ophthalmology, as noted by Dr. St. Leger.
The team’s research, supported by two R01 grants from the National Institutes of Health, also explores the connection between corneal nerves and ocular disease. Research published in NPJ Regenerative Medicine in October 2024, led by Dr. St. Leger and colleagues, investigated how combining a statin with nanovesicles could enhance optic nerve regeneration. This parallel research stream highlights the complex interplay between the nervous system and the immune response in maintaining corneal health. The lab is also investigating how corneal nerves affect the development of ocular disease, specifically focusing on how sensory nerve retraction after HSV-1 infection impacts blink reflexes and ocular surface health.
The Potential of “Living Medicine”
The concept of “living medicine” – using engineered microorganisms to deliver therapeutic agents – is gaining traction in various fields of medicine. In ophthalmology, this approach offers the potential for long-lasting, targeted treatments that could reduce the require for frequent medication applications. The University of Pittsburgh team’s work is particularly innovative because it focuses on utilizing a microbe already present in the eye, minimizing the risk of rejection or adverse immune responses.
Dr. St. Leger’s research also extends to understanding the broader impact of the ocular microbiome on eye health. A 2024 publication in Expert Review of Ophthalmology, co-authored by Dr. St. Leger, explored how the bacterial microbiome impacts ocular surface health and disease. This work underscores the importance of considering the eye not as an isolated organ, but as part of a complex ecosystem.
Further research is needed to assess the long-term safety and efficacy of this “living eye drop” approach. Clinical trials will be essential to determine whether this innovative treatment can translate into a viable option for patients suffering from corneal injuries and other ocular conditions. The team is currently focused on identifying the specific factors regulating sensory nerve retraction and sympathetic nerve growth, hoping to develop therapies that preserve blink reflexes and improve outcomes for patients with HSV-1 infections.
This research represents a promising step forward in the field of ophthalmology, offering a glimpse into a future where “living medicines” could provide sustained, targeted treatments for a wide range of eye diseases.
What are your thoughts on the potential of using genetically modified bacteria to treat eye conditions? Share your comments below, and please share this article with anyone who might find it informative.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
